Takeda Pharmaceutical Co Ltd
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -26.4% | +90.2% | -38.9% | +65.0% | +36.6% | -42.1% | -3.0% | +75.6% | -1.3% | -80.0% | +71.2% | – | |
| – | +2.4% | -0.2% | +2.9% | +0.1% | -2.9% | +1.5% | -4.3% | +1.8% | +3.1% | -14.0% | -0.5% | – | |
| – | +0.9% | -2.8% | -15.4% | +40.1% | -15.1% | -3.7% | -6.2% | +13.3% | -5.0% | +10.7% | -7.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -10,541.6% | – | -235.1% | – | – | -96.8% | -1,273.0% | – | -279.3% | – | -163.2% | – | |
| – | +10.1% | -16.6% | +138.6% | -39.8% | -38.7% | +63.7% | -19.0% | -29.6% | +321.0% | -71.0% | -16.4% | – | |
| – | -77.0% | -18.3% | +154.9% | -52.1% | +53.8% | -83.0% | +68.7% | +45.0% | +377.4% | -74.8% | +51.2% | – | |
| – | +1,425.1% | -93.4% | +1,413.4% | -93.3% | +1,481.2% | -93.3% | +1,392.0% | -94.0% | +1,596.1% | -94.1% | +1,608.6% | – | |
| – | -100.0% | – | +0.0% | +0.0% | +0.0% | +2,555.6% | +3.3% | – | +64,613.2% | +35.4% | -176.2% | – | |
| – | – | – | – | – | +577.1% | -56.8% | – | +166,059.1% | -127.0% | +159.1% | – | – | |
| – | -30.5% | -40.4% | – | -134.8% | +496.1% | -54.0% | -28.8% | -94.4% | +1,506.3% | -59.7% | +132.7% | – | |
| – | -1,876.9% | – | +104.9% | -84.4% | -775.7% | – | – | – | -108.0% | – | – | – | |
| – | -46.2% | +209.1% | -92.2% | +1,021.2% | +73.5% | -60.4% | +8.4% | +131.8% | -53.6% | -93.3% | +628.3% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.